company background image
XENE

Xenon PharmaceuticalsNasdaqGM:XENE Stock Report

Last Price

US$26.00

Market Cap

US$1.4b

7D

-18.6%

1Y

62.8%

Updated

23 Jan, 2022

Data

Company Financials +
XENE fundamental analysis
Snowflake Score
Valuation0/6
Future Growth2/6
Past Performance0/6
Financial Health6/6
Dividends0/6

XENE Stock Overview

Xenon Pharmaceuticals Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics to treat patients with neurological disorders in Canada.

Price History & Performance

Summary of all time highs, changes and price drops for Xenon Pharmaceuticals
Historical stock prices
Current Share PriceUS$26.00
52 Week HighUS$36.42
52 Week LowUS$13.98
Beta1.9
1 Month Change-14.75%
3 Month Change-15.39%
1 Year Change62.81%
3 Year Change228.28%
5 Year Change219.02%
Change since IPO147.62%

Recent News & Updates

Dec 13

Sizing Up Xenon Pharmaceuticals

Today, we look at Xenon Pharmaceuticals, a clinical-stage biotech concern with several products advancing in its pipeline. The stock recently has surged on top of positive mid-stage trial results. The shares have also seen some insider buying lately as well. A full investment analysis follows in the paragraphs below.

Nov 12
We're Hopeful That Xenon Pharmaceuticals (NASDAQ:XENE) Will Use Its Cash Wisely

We're Hopeful That Xenon Pharmaceuticals (NASDAQ:XENE) Will Use Its Cash Wisely

There's no doubt that money can be made by owning shares of unprofitable businesses. By way of example, Xenon...

Shareholder Returns

XENEUS BiotechsUS Market
7D-18.6%-7.4%-6.1%
1Y62.8%-21.7%4.2%

Return vs Industry: XENE exceeded the US Biotechs industry which returned -22% over the past year.

Return vs Market: XENE exceeded the US Market which returned 4.2% over the past year.

Price Volatility

Is XENE's price volatile compared to industry and market?
XENE volatility
XENE Average Weekly Movement8.4%
Biotechs Industry Average Movement10.2%
Market Average Movement6.7%
10% most volatile stocks in US Market15.5%
10% least volatile stocks in US Market2.4%

Stable Share Price: XENE is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 8% a week.

Volatility Over Time: XENE's weekly volatility has decreased from 16% to 8% over the past year.

About the Company

FoundedEmployeesCEOWebsite
1996126Ian Mortimerhttps://www.xenon-pharma.com

Xenon Pharmaceuticals Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics to treat patients with neurological disorders in Canada. Its clinical development pipeline includes XEN496, A Kv7 potassium channel modulator that is Phase III clinical trials for the treatment of KCNQ2 epilepsy encephalopathy; and XEN1101, A Kv7 potassium channel modulator, which is in Phase II clinical trial for the treatment of epilepsy and other neurological disorders. The company’s product candidates also comprise NBI-921352, a selective Nav1.6 sodium channel inhibitor that is in Phase II clinical trials for the treatment of epilepsy; and XEN007, A central nervous system-acting calcium channel modulator, which is in Phase II clinical trials.

Xenon Pharmaceuticals Fundamentals Summary

How do Xenon Pharmaceuticals's earnings and revenue compare to its market cap?
XENE fundamental statistics
Market CapUS$1.37b
Earnings (TTM)-US$65.64m
Revenue (TTM)US$19.85m

69.0x

P/S Ratio

-20.9x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
XENE income statement (TTM)
RevenueUS$19.85m
Cost of RevenueUS$68.54m
Gross Profit-US$48.69m
ExpensesUS$16.95m
Earnings-US$65.64m

Last Reported Earnings

Sep 30, 2021

Next Earnings Date

n/a

Earnings per share (EPS)-1.25
Gross Margin-245.30%
Net Profit Margin-330.69%
Debt/Equity Ratio0%

How did XENE perform over the long term?

See historical performance and comparison

Valuation

Is Xenon Pharmaceuticals undervalued compared to its fair value and its price relative to the market?

5.5x

Price to Book (PB) ratio


Share Price vs. Fair Value

Below Fair Value: XENE ($26) is trading above our estimate of fair value ($23.03)

Significantly Below Fair Value: XENE is trading above our estimate of fair value.


Price To Earnings Ratio

PE vs Industry: XENE is unprofitable, so we can't compare its PE Ratio to the US Biotechs industry average.

PE vs Market: XENE is unprofitable, so we can't compare its PE Ratio to the US market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate XENE's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: XENE is overvalued based on its PB Ratio (5.5x) compared to the US Biotechs industry average (1.9x).


Future Growth

How is Xenon Pharmaceuticals forecast to perform in the next 1 to 3 years based on estimates from 8 analysts?

37.7%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: XENE is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: XENE is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: XENE is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: XENE's revenue (58.4% per year) is forecast to grow faster than the US market (9.1% per year).

High Growth Revenue: XENE's revenue (58.4% per year) is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if XENE's Return on Equity is forecast to be high in 3 years time


Past Performance

How has Xenon Pharmaceuticals performed over the past 5 years?

-14.0%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: XENE is currently unprofitable.

Growing Profit Margin: XENE is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: XENE is unprofitable, and losses have increased over the past 5 years at a rate of 14% per year.

Accelerating Growth: Unable to compare XENE's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: XENE is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (11%).


Return on Equity

High ROE: XENE has a negative Return on Equity (-26.37%), as it is currently unprofitable.


Financial Health

How is Xenon Pharmaceuticals's financial position?


Financial Position Analysis

Short Term Liabilities: XENE's short term assets ($256.3M) exceed its short term liabilities ($12.9M).

Long Term Liabilities: XENE's short term assets ($256.3M) exceed its long term liabilities ($2.6M).


Debt to Equity History and Analysis

Debt Level: XENE is debt free.

Reducing Debt: XENE had no debt 5 years ago.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: XENE has sufficient cash runway for more than 3 years based on its current free cash flow.

Forecast Cash Runway: XENE has sufficient cash runway for 2.9 years if free cash flow continues to reduce at historical rates of 16.2% each year.


Dividend

What is Xenon Pharmaceuticals's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate XENE's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate XENE's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if XENE's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if XENE's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of XENE's dividend in 3 years as they are not forecast to pay a notable one for the US market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

1.4yrs

Average management tenure


CEO

Ian Mortimer (45 yo)

3.83yrs

Tenure

US$1,783,084

Compensation

Mr. Ian C. Mortimer, M.B.A, C.P.A, C.M.A., has been the Chief Executive Officer and Director at Xenon Pharmaceuticals Inc. since June 03, 2021. He has been Director at Perimeter Medical Imaging AI, Inc. si...


CEO Compensation Analysis

Compensation vs Market: Ian's total compensation ($USD1.78M) is below average for companies of similar size in the US market ($USD3.74M).

Compensation vs Earnings: Ian's compensation has increased whilst the company is unprofitable.


Leadership Team

Experienced Management: XENE's management team is not considered experienced ( 1.4 years average tenure), which suggests a new team.


Board Members

Experienced Board: XENE's board of directors are considered experienced (6.7 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: XENE insiders have sold more shares than they have bought in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 46.2%.


Top Shareholders

Company Information

Xenon Pharmaceuticals Inc.'s employee growth, exchange listings and data sources


Key Information

  • Name: Xenon Pharmaceuticals Inc.
  • Ticker: XENE
  • Exchange: NasdaqGM
  • Founded: 1996
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Implied Market Cap: US$1.369b
  • Shares outstanding: 52.66m
  • Website: https://www.xenon-pharma.com

Number of Employees


Location

  • Xenon Pharmaceuticals Inc.
  • 200-3650 Gilmore Way
  • Suite 200
  • Burnaby
  • British Columbia
  • V5G 4W8
  • Canada

Listings


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2022/01/23 23:29
End of Day Share Price2022/01/21 00:00
Earnings2021/09/30
Annual Earnings2020/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.